Clonal medicine targeting DNA damage response eradicates leukemia.

"Competing interests The authors declare no competing interests."

"The authors thank Mission Bio for providing assistance with data generation, data analysis, and data interpretation. This work was supported by R01s CA237286, CA244044, 244179, 247707 and LLS TRP 6628-21 to T.Skorski. The Division of Hematology Biorepository at University of Utah is supported by the National Cancer Institute of the National Institutes of Health under Award Number P30CA042014. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Additional funding came from the Huntsman Center of Excellence in Hematologic Malignancies and Hematology as well as the Hematologic Malignancies and Hematology Disease Center, both at Huntsman Cancer Institute, University of Utah. We thank Dr. Sara H. Small (Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA) for critical reading of the manuscript."